Pelvic Organ Prolapse Treatment Questioned by FDA
WASHINGTON (July 14,2011)—The U.S. Food and Drug Administration (FDA) issued a statement yesterday based on a literature review on the safety and effectiveness of transvaginal placement of surgical mesh for pelvic organ prolapse (POP). These findings indicate that mesh used in transvaginal POP repair introduces risks not present . . . →Read More:Pelvic Organ Prolapse Treatment Questioned by FDA



